Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman Act
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Cipla Limited in Hatch-Waxman litigation matters involving Cipla’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
Celgene Corporation v. Cipla Limited, No. 2-17-cv-06163, 2-18-cv-08964 (D.N.J.)